Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410205 | 0.88 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29608029 | 0.88 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL14300992 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL44676 | 0.80 | KMT2A (0.58) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15981181 | 0.80 | KMT2A (0.58) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL44677 | 0.79 | FABP5 (0.59) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL12016740 | 0.79 | KMT2A (0.56) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29901230 | 0.79 | FABP5 (0.59) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL2782675 | 0.79 | KMT2A (0.56) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29381061 | 0.79 | FABP5 (0.59) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | KMT2A 3983/4885FABP5 1102/4885FABP7 699/4885 |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | KMT2A 3983/4885FABP5 1102/4885FABP7 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.